Yasunori Nakagawa

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

Yu Abe, Masato Muto, Mie Nieda et al. · Experimental Hematology · 2009 · 169 citations

Medicine, Immunology, Pharmacology +17

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacology +9

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes

Yasunori Nakagawa, Shinya Abe, Morito Kurata et al. · American Journal of Hematology · 2006 · 116 citations

Medicine, Cancer Biology, Oncology +16

Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia

Kouhei Yamamoto, Shinya Abe, Yasunori Nakagawa et al. · Leukemia Research · 2004 · 77 citations

Medicine, Genetics, Molecular Biology +7